396 related articles for article (PubMed ID: 8702221)
1. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
ter Haar E; Day BW
Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
[TBL] [Abstract][Full Text] [Related]
2. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
ter Haar E; Hamel E; Balachandran R; Day BW
Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogenic effects of Z-1, 1-dichloro-2,3 diphenyl-2-(4-methoxyphenyl)cyclopropane(5a) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Anticancer Res; 1992; 12(3):585-90. PubMed ID: 1622114
[TBL] [Abstract][Full Text] [Related]
4. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
Reddel RR; Murphy LC; Hall RE; Sutherland RL
Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.
Strobl JS; Peterson VA
J Pharmacol Exp Ther; 1992 Oct; 263(1):186-93. PubMed ID: 1403784
[TBL] [Abstract][Full Text] [Related]
7. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
Reddel RR; Sutherland RL
Cancer Res; 1987 Oct; 47(20):5323-9. PubMed ID: 3652038
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
9. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
Gao HD; Sun JZ; Bi DS; Ma R
Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro.
Lam HY; Ng PK; Goldenberg GJ; Wong CM
Cancer Treat Rep; 1987 Oct; 71(10):901-6. PubMed ID: 3652053
[TBL] [Abstract][Full Text] [Related]
12. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
Liu ZJ; Zhu BT
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
[TBL] [Abstract][Full Text] [Related]
13. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
14. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
16. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells.
Kawamura I; Lacey E; Mizota T; Tsujimoto S; Nishigaki F; Manda T; Shimomura K
Anticancer Res; 1994; 14(2A):427-31. PubMed ID: 8017842
[TBL] [Abstract][Full Text] [Related]
17. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines.
Otto AM; Faderl M; Schönenberger H
Cancer Res; 1991 Jun; 51(12):3217-23. PubMed ID: 2039997
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D.
Mullick A; Chambon P
Cancer Res; 1990 Jan; 50(2):333-8. PubMed ID: 2295073
[TBL] [Abstract][Full Text] [Related]
20. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines.
Pihie AH; Stanslas J; Din LB
Anticancer Res; 1998; 18(3A):1739-43. PubMed ID: 9673398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
